Jump to any asset
849 assets, updated daily
As of September 16, 2026, agilon health, Inc. (AGL) trades at $92.12. CleaRank Financial AI rates it Hold with a fair value of $92.12, in line with the current price. Wall Street's consensus target is $115.00 across 16 analysts. RSI at 41 is in neutral territory, and the price is below its 50-day average of $99.59.
agilon health, inc. (AGL)
agilon health, inc. NYSE
$92.12
-0.2600 (-0.28%)
At close: Sep 15, 4:00 PM EDT
AI Analyst Consensus
53 / 100
agilon health, inc. (AGL) is currently trading at $92.12, below its 50-day moving average of $99.59 but above its 200-day moving average of $53.85. The company's financial health is characterized by a negative EPS of -15.23 and a profit margin of -3.92%, although its price-to-sales ratio of 0.26 is well below the sector median of 3.7. Insiders have recently been net buyers, with $352K in total purchases versus no sales, indicating a degree of confidence in the company's future prospects. Wall Street analysts maintain a consensus 'Hold' rating with a median price target of $115, suggesting a potential upside of 24.8% from the current price. However, forward-looking estimates show revenue contraction in the next quarter and a significant decline in growth estimates over the past five years (-164.4%). The company's ability to turn its profitability around will be key to realizing its valuation potential.
AGL Price Analysis
Market Metrics
Open
$96.25
Day Range
$90.35 to $96.65
Prev Close
$92.38
Volume
202.6K
52-Week Range
$7.48 to $133.04
Market Cap
$1.55B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
On price-to-sales, the yardstick used here in place of P/E, AGL trades at 0.2608x, far below the sector average of 3.70x.
AGL Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 3 quarters, AGL beat estimates 1 times. However, the stock fell 1 times the next day. This suggests positive news is often "priced in" or investors are selling the news.
AGL Analysis
Company's Health
3/5
12-Month Analyst Target
+24.84% Upside
Median of 16 analysts (12-month)
$115.00
AI Technical Analysis
With an RSI of 41.49, agilon health, inc. (AGL) exhibits neutral momentum, neither overbought nor oversold. The stock is currently trading below its 20-day EMA ($92.27) and its 50-day SMA ($99.59), suggesting near-term weakness, but remains above its 200-day SMA ($53.85), indicating a longer-term uptrend is still intact. MACD is negative at -1.66, reinforcing the current bearish short-term trend. Volume on the latest trading day was 202,600, which is 20.2% above the average volume of 168,520, indicating increased investor interest. Key support levels are not clearly defined by long-term averages due to the stock's trading history, but the 200-day SMA at $53.85 represents a significant long-term floor. Resistance may be found near the 50-day SMA at $99.59.
ProTips
- Insiders at agilon health, inc. (AGL) have been net buyers, with $352K in purchases, signaling a degree of confidence in the company's future prospects.
- The stock is trading below its 50-day SMA, indicating potential near-term weakness, but remains above its 200-day SMA, suggesting the longer-term uptrend is intact.
- Given the company's negative EPS and projected near-term revenue contraction, investors should closely monitor upcoming earnings reports for signs of a turnaround in profitability and top-line growth.
Key Catalysts
Bullish
Strong EPS Beat in Q2 2026
agilon health, inc. reported an EPS of $2.15 versus an estimate of $0.27 for the quarter ending June 2026, a significant beat that could signal improving operational efficiency.
Source: Earnings ReportBullish
Insider Net Buying Activity
Insiders have made net purchases totaling $352K with no reported sales, indicating a 'Moderate Buy Signal' and potential confidence in the company's future performance.
Source: Insider TransactionsBearish
Projected Revenue Contraction in Next Quarter
Forward estimates indicate a sales growth of -8.00% for the next quarter, suggesting potential headwinds for the company's top line.
Source: Analyst EstimatesBearish
Negative EPS Surprise and Price Decline
The most recent earnings report showed a negative EPS surprise and a subsequent price drop, highlighting ongoing profitability challenges.
Source: Earnings ReportMarket Outlook
The base case for agilon health, inc. (AGL) over the next 6-12 months anticipates a stabilization around its current valuation, contingent on its ability to demonstrate a path to profitability. Analysts project a significant turnaround in EPS for the next fiscal year, reaching $2.06, which could support a move towards the median analyst target price of $115. The company's below-sector-average price-to-sales ratio may also attract value investors if profitability concerns are addressed. Upside catalysts could include better-than-expected earnings reports, particularly if they show sustained positive EPS growth and revenue stabilization, aligning with the 'Next Year' growth estimate of 7.00%. Conversely, failure to improve profitability, continued revenue contraction, or negative earnings surprises could push the stock towards its downside projection of $14.33, as indicated by Monte Carlo simulations. The company's ability to execute its strategy and manage costs will be critical in determining its trajectory.
Key Statistics
| Market Cap | 1.55B |
|---|---|
| P/E Ratio | N/A (Negative EPS) |
| EPS (TTM) | -15.23 |
| Dividend Yield | 0.00% |
| 52 Week High | 133.04 |
| 52 Week Low | 7.48 |
agilon health, inc. (AGL) presents a challenging valuation profile with a negative EPS of -15.23, making its P/E ratio mathematically negative and thus not comparable to sector averages. Its price-to-sales ratio of 0.26 is significantly lower than the sector median of 3.7, suggesting it is undervalued on a sales basis, but this is overshadowed by its profitability issues. The company's return on equity is a significantly negative -78.94%, indicating severe inefficiency in generating profits from shareholder equity. Despite a low debt-to-equity ratio of 0.15, which is favorable, the company's operating margin of 1.30% and net profit margin of -3.92% highlight significant profitability challenges. While revenue growth was 7.2% in the last reported period, forward estimates suggest a contraction in the next quarter and a negative growth rate for the current year, raising concerns about the company's ability to improve its financial performance.
Earnings & Growth Analysis
agilon health, inc. (AGL) demonstrated a significant earnings beat in the quarter to June 2026, reporting an EPS of $2.15 against an estimate of $0.27, a surprise of 696.3%. However, this was followed by a substantial price drop of -19.49%. Prior to that, the quarter to March 2026 also saw a large EPS beat of $2.32 versus an estimate of $0.93, accompanied by a strong price increase of 117.81%. The most recent quarter to August 2026 showed a negative EPS surprise of -30.66% with a price decline of 19%.
Key Risks
The primary risk for agilon health, inc. (AGL) is its persistent unprofitability, evidenced by a negative EPS of -15.23 and a negative profit margin of -3.92%. Additionally, forward revenue estimates indicate a contraction in the next quarter, raising concerns about top-line growth sustainability. The stock's neutral RSI and trading below its 50-day SMA suggest potential for further downside pressure in the short term.
Technical Indicators
| RSI (14) | 41.49 |
|---|---|
| MACD | -1.66 |
| SMA 50 | 99.59 |
| SMA 200 | 53.85 |
RSI
Neutral
SMA Cross
Bullish
Price vs SMA
Bearish
MACD
Bearish
Golden Cross in effect with the 50-day SMA ($99.59) above the 200-day SMA ($53.85), price is trading below the 50-day SMA.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.10
Weak correlation
Nasdaq 100 (QQQ)
+0.10
Weak correlation
Bitcoin (BTC)
+0.42
Moderate correlation
Gold (XAU)
+0.11
Weak correlation
Check Custom Correlation
How does any other asset move with AGL? One year of daily closes, Pearson correlation.
Try
AGL Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Entry Strategies pick an entry style
Conservative
$91.20
Slight discount to current
Wait for small dip
Aggressive
$92.12
At current price
Enter now if confident
Risk Management
STOP LOSS
$81.66
MAX LOSS
-10.5%
Volatility-Adjusted Stop Loss
Calculated based on RSI (41.5) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$93.93
+3% (Conservative)
+2.0% (Aggressive)
TARGET 2
$95.76
+5% (Conservative)
+4.0% (Aggressive)
TARGET 3
$98.49
+8% (Conservative)
+6.9% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
High-Volatility Risk Disclaimer
AGL is classified as a high-volatility asset (Daily Vol: 5.84%). Aggressive price swings can lead to rapid capital loss. Liquidity risks may prevent exiting trades at desired prices. This AI-generated analysis is for educational purposes only and is not financial advice. Generated on September 16, 2026.Growth of $10,000
A $10,000 investment in AGL in April 2021 would be worth about $1,189 today, compared with about $18,212 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in AGL today could grow to about $2,352 by 2036 in the base case, with a bull case near $17,842 and a bear case around $310. Projections are statistical simulations, not guarantees.
AGL Stock Price Prediction: 2030
CleaRank's simulation projects a price near $51.63 for AGL by 2030 in the base case, from $92.12 today (0.6x over 4 years). The downside path ends near $14.33. These are outcomes of a Monte Carlo simulation run on AGL's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $41.99 | $79.71 | $151 |
| 2028 | $27.87 | $68.97 | $171 |
| 2029 | $19.67 | $59.67 | $181 |
| 2030 | $14.33 | $51.63 | $186 |
| 2031 | $10.66 | $44.67 | $187 |
| 2032 | $8.04 | $38.65 | $186 |
| 2033 | $6.14 | $33.44 | $182 |
| 2034 | $4.72 | $28.94 | $177 |
| 2035 | $3.66 | $25.04 | $171 |
| 2036 | $2.86 | $21.66 | $164 |
Method: 10,000 simulated price paths using AGL's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
AGL Insider Trading Analysis
Bought
$352.0K
2 Transactions
Sold
None
No open-market sells
Insiders
13
Active Traders
Avg Transaction
$176.0K
Moderate size
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 18, 2023 | CD&R INVESTMENT ASSOCIATES IX, LTD.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 94.2M | $2.0B |
| Sep 14, 2021 | CD&R INVESTMENT ASSOCIATES IX, LTD.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 17.9M | $518.9M |
| Aug 11, 2022 | CD&R INVESTMENT ASSOCIATES IX, LTD.
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 11.3M | $276.1M |
| Jul 7, 2022 | DESAI VEERAL
Officer
|
Sell | 319.1K | $8.0M |
| Apr 20, 2022 | DESAI VEERAL
Officer
|
Sell | 212.7K | $4.8M |
| Sep 14, 2021 | HALKIAS THEODORE
Officer
|
Sell | 158.6K | $4.6M |
| Sep 14, 2021 | MANSUKANI SHARAD S.
Director
|
Sell | 156.3K | $4.5M |
| Mar 16, 2022 | DESAI VEERAL
Officer
|
Sell | 197.3K | $4.0M |
| Nov 4, 2021 | SOBOTKA GLENN
Officer
|
Sell | 150.0K | $3.8M |
| Sep 14, 2021 | DESAI VEERAL
Officer
|
Sell | 121.0K | $3.5M |
Page 1 of 1
Frequently Asked Questions
What is agilon health, inc.'s stock price forecast for 2030?
Based on Monte Carlo simulations, agilon health, inc.'s stock price is projected to be $51.63 in 2030 under base case assumptions, with a downside projection of $14.33 and an upside projection of $185.99. These are statistical outcomes, not guarantees.
Is agilon health, inc. stock a buy right now?
agilon health, inc. (AGL) is currently rated a 'Hold' by Wall Street analysts, with a median price target of $115 suggesting a 24.8% upside. While insiders are net sellers, the company's negative EPS and projected near-term revenue contraction present significant risks.
What are the key risks facing agilon health, inc.?
The main risks include persistent unprofitability, with a negative EPS of -15.23, and projected revenue contraction in the upcoming quarter. The stock's neutral RSI and position below its 50-day SMA also indicate potential short-term weakness.
How does agilon health, inc. compare to its sector peers?
agilon health, inc. (AGL) trades at a price-to-sales ratio of 0.26, significantly below the sector median of 3.7. However, its profitability metrics, including a negative profit margin of -3.92% and a significantly negative return on equity of -78.94%, lag far behind sector averages.
What is the recent earnings performance of agilon health, inc.?
The company reported a significant EPS beat in the quarter to June 2026 ($2.15 actual vs $0.27 estimate), but this was followed by a price drop. Previous quarters also showed earnings beats, but the most recent earnings report indicated a negative EPS surprise and a price decline.
What is the outlook for agilon health, inc.'s revenue growth?
While the company reported 7.2% revenue growth in its last period, forward estimates project a contraction of -8.00% in the next quarter and a -2.00% growth for the current year. However, next year's revenue is projected to grow by 7.00%.
Are agilon health, inc. insiders buying or selling stock?
Insiders at agilon health, inc. (AGL) are net buyers, having purchased $352K worth of stock with no reported sales in recent filings. This 'Moderate Buy Signal' suggests some level of insider confidence.